EPISODE · Nov 17, 2025 · 10 MIN
Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Olyer walks us through that and the whole pipeline
from BiotechTV - News · host BiotechTV
He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners.
Embed this episode
Ready to play
Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Olyer walks us through that and the whole pipeline
0:00
10:09
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 10 minutes long.
When was this BiotechTV - News episode published?
This episode was published on November 17, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!